iZafe Group

iZafe Group FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of iZafe Group (IZAFE B.ST) as of Nov 19, 2026 is 174.60 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 60.35 % — a change of 189.29% (higher).

FCF Conversion

174.60 %

YoY

189.29%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of iZafe Group is 2025 174.60 % . FCF Conversion Rate (FCF/EBITDA) of iZafe Group was 2024 60.35 % . It decreases by 189.29% higher compared to the previous year.

The iZafe Group FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
203.05 SEK
Jan 1, 2019
84.31 SEK
Jan 1, 2020
204.99 SEK
Jan 1, 2021
92.92 SEK
Jan 1, 2022
102.51 SEK
Jan 1, 2023
39.51 SEK
Jan 1, 2024
60.35 SEK
Jan 1, 2025
174.60 SEK
The iZafe Group FCF Conversion history
YEARFCF ConversionYoY
174.60 %+189.29%
60.35 %+52.75%
39.51 %-61.45%
102.51 %+10.32%
92.92 %-54.67%
204.99 %+143.15%
84.31 %-58.48%
203.05 %-10.54%
226.99 %+165.01%
85.65 %+24.22%
68.95 %+150.26%
27.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iZafe Group Stock analysis

What does iZafe Group do? iZafe Group AB develops medical and digital security solutions, including Dosell, a patented drug dispenser for home medication with remote monitoring, and MediKoll, an app providing medication side effect and allergy information. The company serves pharmaceutical companies, hospitals, care homes, and pharmacies in the global market. Its products target patients and healthcare providers seeking secure, remote medication management and personalized health information. Dosell is under development as a home medication solution, while MediKoll offers real-time data on medication reactions. The firm's revenue comes from selling these digital tools to healthcare institutions and pharmaceutical partners, focusing on improving patient safety and reducing medication errors through technology. iZafe Group AB's business model relies on the global healthcare sector's demand for innovative digital tools. The company's offerings are tailored for pharmaceutical firms, hospitals, care homes, and pharmacies, leveraging remote monitoring capabilities to address medication management challenges in home and clinical settings. iZafe Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iZafe Group stock

FCF Conversion Rate (FCF/EBITDA) of iZafe Group is 174.60 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of iZafe Group changed from 60.35 % to 174.60 %, representing a 189.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) iZafe Group since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s iZafe Group with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — iZafe Group

All Key Metrics — iZafe Group